Skip To Main Content

Frequently asked questions

Find answers to your frequently asked questions

It’s normal to have questions before starting a new treatment. You might find answers to some of your questions below.

Tzield is medicine used to delay the start of Stage 3 Type 1 diabetes (T1D) in adults and children aged 8 years and older who have Stage 2 T1D.1,2 Stage 2 T1D means you have two or more T1D autoantibodies, abnormal blood sugar levels, and do not have Type 2 diabetes.1,2 You may find more helpful information here.

In Type 1 diabetes, the body mistakenly attacks cells in the pancreas that produce insulin, called beta cells. Tzield sticks to immune cells to help slow down the attack on beta cells so that they can keep producing insulin for a little longer.1 You may find more helpful information here.

Tzield is given once a day for 14 days and administered through the veins (an infusion). Each infusion takes at least 30 minutes, and there will be some time before and after to set-up the infusion and monitor how you are doing.1,2 You may find more helpful information here.

If one of your infusions is missed, your doctor or nurse will continue the treatment on the next scheduled day to complete the 14-day course. You won’t receive two infusions on the same day.1

Like all medicines, Tzield can cause side effects, although not everybody gets them.1 It is important to know what to expect and what to look out for. Please read the Patient Information Leaflet and speak to your doctor or nurse if you have any questions or concerns about side effects. You may find more helpful information here.

Your care team will monitor your health before, during, and after treatment and manage your ongoing care. Talk to them if you’d like to know more about individual treatment aims. You can find out more about how Tzield works here.

Additional information and patient support is available if you need it. Visit our Resources & support page or head straight to:

DigiBete at https://www.digibete.org/
Breakthrough T1D at https://breakthrought1d.org.uk/
Diabetes UK at https://www.diabetes.org.uk/

By following the links above, you will be directed to independent websites which Sanofi has no control over. Sanofi accepts no responsibility for the content or availability of the websites.

Tell your doctor or nurse about the medicines you take, have recently taken, or plan to take. This includes prescription and non-prescription medicines, vitamins, supplements, and vaccines.1

If you feel unwell before, during, or after your infusion, talk to your doctor or nurse.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple app Store.

Alternatively, you can report side effects to Sanofi on Tel: 0800 0902 314 or send via email to UK-drugsafety@sanofi.com. By reporting side effects, you can help provide more information on the safety of this medicine.

It’s important to know the symptoms of Stage 3 autoimmune T1D (T1D) so that you can look out for them. The most common symptoms are needing to wee more often, being constantly thirsty, feeling incredibly tired and lacking energy, and losing weight without trying to.3 You may find more helpful information here.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple app Store.

Alternatively, you can report side effects to Sanofi on Tel: 0800 0902 314 or send via email to UK-drugsafety@sanofi.com. By reporting side effects, you can help provide more information on the safety of this medicine.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects that you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

 

Tell your doctor or nurse if you are pregnant or plan to become pregnant. Tzield may harm your unborn baby. Do not have Tzield during pregnancy – and at least 30 days before a planned pregnancy.1

Tell your doctor or nurse if you are breastfeeding or plan to breastfeed. It is not known if Tzield passes into your breast milk and if it can harm your baby. Talk to your doctor about the best way to feed your baby if you have Tzield. If you are breastfeeding, it is best to pump and throw away your breast milk during treatment with Tzield – and for 20 days after treatment.1

Tzield is a medicine used to delay the start of Stage 3 Type 1 diabetes. This condition happens when the body cannot make enough insulin on its own and may need insulin injections. This medicine is used in adults and children aged 8 years and older who have Stage 2 Type 1 diabetes.1

If you have any questions on how Tzield works or about your treatment with Tzield, ask your doctor.

This website is not intended to be a substitute for medical advice. Please refer to the Patient information leaflet and the Patient Guide for full safety information. You may have received these items from your doctor already.

 

References:

  1. TZIELD® (teplizumab) UK Patient Information Leaflet. Accessed: November 2025.
  2. TZIELD® (teplizumab) UK Summary of Product Characteristics. Accessed: November 2025.
  3. Diabetes UK. Type 1 diabetes symptoms. Available at: https://www.diabetes.org.uk/about-diabetes/type-1-diabetes/symptoms. Accessed: November 2025.

© 2025 Sanofi. All rights reserved. MAT-XU-2501109 (V1.0) | November 2025